These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32315118)

  • 21. Rate of β-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials.
    Guo T; Dukart J; Brendel M; Rominger A; Grimmer T; Yakushev I;
    Alzheimers Dement; 2018 Nov; 14(11):1387-1396. PubMed ID: 30420035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
    Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
    JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults: A Machine Learning Approach Using A4 Data.
    Petersen KK; Lipton RB; Grober E; Davatzikos C; Sperling RA; Ezzati A
    Neurology; 2022 Jun; 98(24):e2425-e2435. PubMed ID: 35470142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease.
    Insel PS; Kumar A; Hansson O; Mattsson-Carlgren N;
    Neurology; 2023 Jul; 101(1):e20-e29. PubMed ID: 37085326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal Trajectories of the Cognitive Function Index in the A4 Study.
    Amariglio RE; Grill JD; Rentz DM; Marshall GA; Donohue MC; Liu A; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):838-845. PubMed ID: 39044492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations of Widowhood and β-Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults.
    Biddle KD; Jacobs HIL; d'Oleire Uquillas F; Zide BS; Kirn DR; Properzi MR; Rentz DM; Johnson KA; Sperling RA; Donovan NJ
    JAMA Netw Open; 2020 Feb; 3(2):e200121. PubMed ID: 32101313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
    Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
    Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects.
    Squarzoni P; Faria DP; Yassuda MS; Porto FHG; Coutinho AM; Costa NAD; Nitrini R; Forlenza OV; Duran FLS; Brucki SMD; Buchpiguel CA; Busatto GF
    J Alzheimers Dis; 2020; 78(1):229-244. PubMed ID: 32986673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study.
    Rentz DM; Rosenberg PB; Sperling RA; Donohue MC; Raman R; Liu A; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):814-822. PubMed ID: 39044489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
    Groot C; Smith R; Stomrud E; Binette AP; Leuzy A; Wuestefeld A; Wisse LEM; Palmqvist S; Mattsson-Carlgren N; Janelidze S; Strandberg O; Ossenkoppele R; Hansson O
    Brain; 2023 Apr; 146(4):1580-1591. PubMed ID: 36084009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Nakamura A; Cuesta P; Fernández A; Arahata Y; Iwata K; Kuratsubo I; Bundo M; Hattori H; Sakurai T; Fukuda K; Washimi Y; Endo H; Takeda A; Diers K; Bajo R; Maestú F; Ito K; Kato T
    Brain; 2018 May; 141(5):1470-1485. PubMed ID: 29522156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.
    Doraiswamy PM; Sperling RA; Johnson K; Reiman EM; Wong TZ; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Joshi AD; Lu M; Grundman M; Mintun MA; Skovronsky DM; Pontecorvo MJ; ;
    Mol Psychiatry; 2014 Sep; 19(9):1044-51. PubMed ID: 24614494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
    Gaubert S; Raimondo F; Houot M; Corsi MC; Naccache L; Diego Sitt J; Hermann B; Oudiette D; Gagliardi G; Habert MO; Dubois B; De Vico Fallani F; Bakardjian H; Epelbaum S;
    Brain; 2019 Jul; 142(7):2096-2112. PubMed ID: 31211359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels.
    Brugulat-Serrat A; Cañas-Martínez A; Canals-Gispert L; Marne P; Gramunt N; Milà-Alomà M; Suárez-Calvet M; Arenaza-Urquijo EM; Grau-Rivera O; González-de-Echávarri JM; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL; Sánchez-Benavides G;
    J Alzheimers Dis; 2021; 84(1):119-128. PubMed ID: 34569957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determining clinically meaningful decline in preclinical Alzheimer disease.
    Insel PS; Weiner M; Mackin RS; Mormino E; Lim YY; Stomrud E; Palmqvist S; Masters CL; Maruff PT; Hansson O; Mattsson N
    Neurology; 2019 Jul; 93(4):e322-e333. PubMed ID: 31289148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Financial Management Skills in Aging, MCI and Dementia: Cross Sectional Relationship to 18F-Florbetapir PET Cortical β-amyloid Deposition.
    Tolbert S; Liu Y; Hellegers C; Petrella JR; Weiner MW; Wong TZ; Murali Doraiswamy P
    J Prev Alzheimers Dis; 2019; 6(4):274-282. PubMed ID: 31686100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.